Diaceutics PLC’s Post

We are excited to present our experience with the use of Anifrolumab in SLE patients. The aim of this study was to examine the patient perspective and present our clinical experience of the treatment. This was a cross-sectional, non-interventional qualitative interview study employing a hybrid approach, combining primary data from one-on-one qualitative patient interviews and secondary data from a collection of patient data from electronic medical records (EMR). Patients reported overall symptom improvement with Anifrolumab, despite ongoing disease impact. EMR data demonstrated reduced disease activity and decreased corticosteroid usage post-treatment. This study enhances our understanding of the patient perspective of Anifrolumab treatment as well as providing us with real world data on the efficacy of the treatment. This research is published in Lupus and can be accessed here: https://lnkd.in/dTGYxUKg Anne Troldborg, Daniel Eek, Lauren Remkus, Bent Deleuran  #RheumAarhus #Lupus #SLEtreatment #patientperspective

🙌 We are thrilled with the incredible turnout for this CME-accredited symposium led by Prof Julian Gillmore. If you miss the live session or want to revisit the valuable research shared, you can now watch the entire series online 🔗 https://ow.ly/KzLZ50TpNfg Enhance your diagnostic skills in ATTR-CM by: 🌟 Understanding recent epidemiological data 🌟 Identifying patients for detailed diagnosis 🌟 Exploring emerging therapeutic agents #CardioVascular #ATTRCM #MedicalEducation #CME

Our third annual Clinical Hereditary Disease Diagnostics Summit is almost here! 🩺 Hear from industry leaders as they tackle the current state of clinical exome testing for newborn screening and rare and undiagnosed diseases. Topics will include: ☑️ Emerging trends and tech advancements in genetic testing ☑️ Opportunities and challenges in bringing clinical exome testing in-house ☑️ How to integrate genetic testing into clinical practice while considering efficiency, cost and ethics Save your seat today ⬇️

Listen to a recent KoNECT webinar where our early phase experts discussed strategic approaches for first-in-human (FIH) studies and early clinical development. During this session we explored best practices in cohort planning and dose selection in first-in-human (FIH) studies, options for running a hAME study, progression into early patient studies, and the use of pharmacometric analyses using data from FIH studies to facilitate informed decision making. https://ow.ly/Pey750TKz1e?

The clinical data BriaCell presented at #ASCO24 shows that Bria-IMT™ offers extended progression-free survival and clinical benefit in heavily pre-treated, ADC resistant #breastcancer patients versus those in other similar studies. Learn more: https://bit.ly/3KsI9hV #metastaticbreastcancer

With the launch of our first data collection program for v-ATPase patients occurring next week with RARE-X, this edition of #FactFriday explains just why exactly patient registries are so vital for rare disease communities! 1) Data Collection: They gather uniform data across a population defined by a particular disease, which is essential when patient numbers are small and scattered. 2) Natural History Documentation: Registries support the documentation of the natural history of a disease, providing invaluable insights into disease progression and outcomes. 3) Research Collaboration: They facilitate collaboration among researchers, healthcare providers, and patients, enabling data sharing and increasing research possibilities. 4) Personalized Medicine: Registries contribute to evidence-based personalized medicine, helping to define cases, revise disease classifications, and evaluate diagnostic and therapeutic strategies. 5) Improving Patient Care: By tracking patients over time, registries can improve patient care and help identify the most effective treatments. To sum it up, patient registries are crucial in transforming the landscape of rare disease research. They empower patients, enhance collaboration, and pave the way for breakthroughs that can change lives. #RareDiseaseResearch #PatientRegistries #HopeInNumbers #BeCounted #vatpase

This proof-of-concept observational study shows that dd-cfDNA, a noninvasive biomarker for rejection risk, can be used to help inform physician decisions regarding IST reduction in KTx patients, along with patient evaluation and other clinical factors. #OpenAccess tinyurl.com/45s8sr9z

Digital Therapeutics: The Future Of Personalized Medicine! In this article, our CEO Ayush Jain, discusses the transformative potential of digital therapeutics (DTx) in the healthcare industry. As chronic diseases become more prevalent, the need for tailored, evidence-based treatment solutions has never been greater. Discover how DTx is reshaping chronic disease management, enhancing patient engagement, and paving the way for a more holistic, patient-centered healthcare future. Read the full article here. 👇 https://lnkd.in/dyuQr2Qx #DigitalHealth #PersonalizedMedicine #ChronicDisease #Innovation #HealthcareTechnology Innovation & Tech Today American Medical Association American Hospital Association Digital Health Insights Becker's Healthcare FDA McKinsey & Company Pravin Uttarwar Manisha Khadge

Did you know that chronic diseases account for a whopping 84% of deaths globally? That's a staggering number. Digital therapeutics (DTx) are transforming the way we treat chronic conditions. These aren't just apps; they're evidence-based treatments delivered right to your smartphone for personalized care, improved engagement, and better outcomes for chronic conditions like diabetes, hypertension, and mental health. Read the article to learn more! Innovation & Tech Today American Medical Association American Hospital Association Digital Health Insights Becker's Healthcare BioSpace McKinsey & Company FDA Manisha Khadge Pravin Uttarwar #digitaltherapeutics #personalizedmedicine #healthcare #wellness #healthtech #futureofhealthcare

If you are in clinical development, you understand it is important to optimize your study design early on to improve the probability of a trial’s success. Phesi’s Trial Accelerator platform has the ability to leverage AI and data analytics to create digital twins, improve protocol parameters, determine site selection and more. For the latest 2023 insights, check out the paper below.